Stock AKRO AKERO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
21.02 USD -4.54% Intraday chart for Akero Therapeutics, Inc. +4.68% -9.98%
Apr. 30 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer CI
Mar. 08 Akero Therapeutics Raises $367 Million From Share Offering MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
GL
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
AQ
AKRO Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
PR
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc.
PR
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
BU
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
BU
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
BU
AKERO THERAPEUTICS CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
PR
AKRO ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
NE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
BU
Akero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Action
BU
Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
BU
AKRO Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
BU
The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
BU
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc.
PR
AKRO Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
PR
NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.
PR
NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AKRO Stock
  4. News Akero Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW